Business Context and Reporting Period
This Form 8-K, dated December 31, 2019, is a Current Report filed by Proteon Therapeutics, Inc. (PRTO). The filing serves to supplement the Definitive Proxy Statement regarding a planned merger with ArTara Therapeutics, Inc. The primary purpose is to address disclosure claims made in four putative stockholder lawsuits filed between November and December 2019. Proteon denies the allegations but voluntarily provided additional information to moot the plaintiffs' claims and avoid business delays.
Key Financial Metrics and Valuation Data
The filing does not contain historical revenue, profit, or cash flow statements for Proteon Therapeutics, Inc. for the period ended December 31, 2019. However, it discloses detailed financial projections and valuation methodologies for the target company, ArTara Therapeutics, Inc., prepared by financial advisor Wainwright:
- ArTara EBIT Projections: Projected losses from FY2020 ($20.6M) through FY2025 ($25.3M), turning profitable in FY2026 ($27.4M) and growing to $693.2M by FY2034.
- Valuation Methodology: Wainwright utilized Discounted Cash Flow (DCF) analysis with a 25% discount rate base case and a 23% tax rate.
- Enterprise Value Range: Calculated between $214.1 million and $403.8 million using terminal multiples (4x-12x EBIT) and between $103.6 million and $422.7 million using perpetuity growth (1%-3%).
- Midpoint Valuations: $308.8 million (terminal multiple) and $211.0 million (perpetuity growth).
- Minimum Combined Valuation: $141.7 million, which would result in existing Proteon stockholders owning 10.8% of the combined company.
Material Changes and Supplemental Disclosures
The filing details specific amendments to the Proxy Statement regarding alternative strategic transactions considered by Proteon prior to the ArTara merger:
- Company G: Advisors indicated Proteon shareholders would receive 10-20% ownership. Company G required Proteon to provide the full management team and raise additional funding.
- Company E: Proteon shareholders would receive "well under 50%" ownership. Company E required a capital raise and additional management members.
- Company F: CEO stated Proteon shareholders would own approximately 10% in a reverse merger. Company F needed to raise approximately $60 million.
- Company H: Proposed a merger with a financing term sheet containing a "full ratchet" provision, deemed inferior by Proteon.
- Revised Proposal Terms: A $20 million investment was based on a $200 million valuation but included a full ratchet provision allowing investors to invest at the lower of the $200 million valuation or the trading value at closing and 45 days post-closing.
Outlook, Risks, and Contingencies
Merger Status: A special meeting of stockholders is scheduled for January 9, 2020, to approve the merger of REM 1 Acquisition, Inc. (Proteon subsidiary) with ArTara. ArTara will survive as a wholly owned subsidiary of Proteon.
Litigation Risks: Four lawsuits allege the proxy statement omits material information. Proteon intends to defend vigorously but is supplementing disclosures to resolve these claims.
Forward-Looking Risks: Significant risks include the failure to obtain stockholder approval, inability to secure anticipated financing, clinical trial outcomes for ArTara's lead asset (TARA-002), and the ability of the combined company to remain listed on Nasdaq.
Investor Verification Checklist
- Verify the outcome of the stockholder vote scheduled for January 9, 2020, regarding the ArTara merger.
- Confirm the status of the four pending stockholder lawsuits and whether the supplemental disclosures have resolved the claims.
- Review the Definitive Proxy Statement (File No. 333-234549) for the full text of the Merger Agreement and risk factors.
- Assess the feasibility of the anticipated financing required to close the merger and support the combined company's operations.
- Monitor the clinical development progress of ArTara's TARA-002 asset, which underpins the valuation projections.